Uloric and Dermatitis - a phase IV clinical study of FDA data

Summary:

Dermatitis is reported as a side effect among people who take Uloric (febuxostat), especially for people who are female, 50-59 old, also take Humira, and have Psoriatic arthropathy.

The phase IV clinical study analyzes which people have Dermatitis when taking Uloric. It is created by eHealthMe based on reports of 7,878 people who have side effects when taking Uloric from the FDA, and is updated regularly.

What is Uloric?

Uloric has active ingredients of febuxostat. It is often used in gout. eHealthMe is studying from 8,067 Uloric users. Check the latest studies of Uloric.

What is Dermatitis?

Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it) is found to be associated with 1,551 drugs and 1,231 conditions by eHealthMe. Check the latest studies of Dermatitis.

On Jul, 13, 2026

7,878 people reported to have side effects when taking Uloric.
Among them, 25 people (0.32%) have Dermatitis.

Among these 25 people:

What is the gender of people who have Dermatitis when taking Uloric? *

female: 90 %
male: 10 %

What is the age of people who have Dermatitis when taking Uloric? *

What are other drugs people take besides Uloric? *

What are other side effects people have besides Dermatitis? *

Rashes (redness): 23 people, 92.00%
Skin Ulcer: 22 people, 88.00%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 22 people, 88.00%
Tongue Disorder (disease of tongue): 22 people, 88.00%
Therapeutic Response Decreased (less preventive response): 22 people, 88.00%
Joint Swelling: 22 people, 88.00%
Tenosynovitis (inflammation of the fluid-filled sheath (called the synovium) that surrounds a tendon): 22 people, 88.00%
Tendonitis (a condition that causes pain and swelling of tendons): 22 people, 88.00%
Synovitis (inflammation of the synovial membrane): 22 people, 88.00%
Enthesopathy (disorder of entheses (bone attachments)): 22 people, 88.00%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 22 people, 88.00%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 22 people, 88.00%
Psoriasis (immune-mediated disease that affects the skin): 21 people, 84.00%
Rashes (redness): 14 people, 56.00%
Adenomatous Polyposis Coli ((fap) is an inherited condition in which numerous polyps form mainly in the epithelium of the large intestine): 5 people, 20.00%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 4 people, 16.00%
Ankylosing Spondylitis (type of arthritis affecting the spine): 3 people, 12.00%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 2 people, 8.00%
Asthma: 2 people, 8.00%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 4.00%

* Approximation only. Some reports may have incomplete information.

Do you take Uloric and have Dermatitis?

- Check whether Dermatitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Uloric:

Uloric (8,067 reports)

Dermatitis treatments and more:

Dermatitis (30,577 reports)

Browse all side effects of Uloric:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Dermatitis:

Dermatitis (1,551 drugs)

Browse all the conditions that are associated with Dermatitis:

Dermatitis (1,231 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on febuxostat (the active ingredients of Uloric) and Uloric (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.